Tarsus Pharmaceuticals, Inc. (TARS)

USD 52.7

(-1.05%)

Market Cap (In USD)

2.01 Billion

Revenue (In USD)

17.44 Million

Net Income (In USD)

-135.89 Million

Avg. Volume

776.34 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
18.99-56.77
PE
-
EPS
-
Beta Value
1.004
ISIN
US87650L1035
CUSIP
87650L103
CIK
1819790
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Bobak R. Azamian M.D.
Employee Count
-
Website
https://www.tarsusrx.com
Ipo Date
2020-10-16
Details
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.